Statement
Univ. Prof. Dr. Dr. h. c. Friedhelm Beyersdorf

“We have developed a novel therapy for resuscitation from the findings of our years of clinical research, which we call CARL Therapy. The new therapy is based on extracorporeal circulation, through which the organism damaged by the cardiac arrest is additionally treated. During a CARL therapy – and this is new – numerous values are measured that provide information about the patient’s condition. The patient’s treatment is targeted accordingly by adjusting the flow, composition and temperature of the blood to his or her individual needs.”

Univ. Prof. Dr. Dr. h. c. Friedhelm Beyersdorf
Founder & Initiator
Former Medical Director of the Clinic of Cardiovascular Surgery at the Medical Center – University of Freiburg

Statement
Prof. Dr. Trummer

“With the newly developed CARL Therapy, we hope to be able to shift the previous limits of resuscitation. It is the first personalized therapy that takes into account the individual condition of a cardiac arrest patient and in this way helps to prevent cell and organ damage of the kind that occurs after blood flow is restored.”

Prof. Dr. Georg Trummer
Clinic for Cardiovascular Surgery I Department University Heart Center I Freiburg University Hospital

Statement
Prof. Dr.-Ing. Benk

“In order to establish CARL Therapy in clinical practice, numerous innovative approaches in the field of medical technology were required. The visionary challenge was to be able to automatically control and thus monitor both the physical and biochemical perfusion conditions during extracorporeal circulation, and to do so during emergency operations both in and outside the hospital.

We have risen to this challenge – and today we have reached the point where our smart system can start its journey into the clinics.”

Prof. Dr.-Ing. Christoph Benk
Managing Director I Resuscitec GmbH